{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:34:19Z","timestamp":1769117659165,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>4-Sodium phenylbutyrate (PBA) has been reported to inhibit endoplasmic reticulum stress and histone deacetylation (HDAC), both of which are novel therapeutic targets for cardiac hypertrophy and heart failure. However, it is unclear whether PBA can improve heart function. Here, we tested the effects of PBA and some other HDAC inhibitors on cardiac dysfunction induced by pressure overload. Transverse aortic constriction (TAC) was performed on male C57BL\/6 mice. PBA treatment (100\u2009mg\/kg, 6 weeks) unexpectedly led to a higher mortality, exacerbated cardiac remodelling and dysfunction. Similar results were noted in TAC mice treated with butyrate sodium (BS), a PBA analogue. In contrast, other HDAC inhibitors, valproic acid (VAL) and trichostatin A (TSA), improved the survival. All four HDAC inhibitors induced histone H3 acetylation and inhibited HDAC total activity. An individual HDAC activity assay showed that rather than class II<jats:sub>a<\/jats:sub> members (HDAC4 and 7), PBA and BS predominantly inhibited class I members (HDAC2 and 8), whereas VAL and TSA inhibited all of them. These findings indicate that PBA and BS accelerate cardiac hypertrophy and dysfunction, whereas VAL and TSA have opposing effects.<\/jats:p>","DOI":"10.1038\/srep34036","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T09:29:51Z","timestamp":1474882191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition"],"prefix":"10.1038","volume":"6","author":[{"given":"Jing","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"BFsrep34036_CR1","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.01303.2004","volume":"289","author":"K Berenji","year":"2005","unstructured":"Berenji, K., Drazner, M. H., Rothermel, B. A. & Hill, J. A. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289, H8\u2013H16 (2005).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep34036_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.RES.0000197782.21444.8f","volume":"98","author":"J Backs","year":"2006","unstructured":"Backs, J. & Olson, E. N. Control of cardiac growth by histone acetylation\/deacetylation. Circ Res 98, 15\u201324 (2006).","journal-title":"Circ Res"},{"key":"BFsrep34036_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/01.CIR.0000137836.95625.D4","volume":"110","author":"K Okada","year":"2004","unstructured":"Okada, K. et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: Possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 110, 705\u2013712 (2004).","journal-title":"Circulation"},{"key":"BFsrep34036_CR4","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1291\/hypres.31.1977","volume":"31","author":"H Zhao","year":"2008","unstructured":"Zhao, H. et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 31, 1977\u20131987 (2008).","journal-title":"Hypertens Res"},{"key":"BFsrep34036_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1161\/CIRCULATIONAHA.109.917914","volume":"122","author":"HY Fu","year":"2010","unstructured":"Fu H. Y. et al. Ablation of c\/ebp homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 122, 361\u2013369 (2010).","journal-title":"Circulation"},{"key":"BFsrep34036_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/sj.leu.2404050","volume":"20","author":"P Maslak","year":"2006","unstructured":"Maslak, P. et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20, 212\u2013217 (2006).","journal-title":"Leukemia"},{"key":"BFsrep34036_CR7","unstructured":"Carducci, M. A. et al. A phase i clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7, 3047\u20133055 (2001)."},{"key":"BFsrep34036_CR8","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","volume":"23","author":"MA Rudek","year":"2005","unstructured":"Rudek, M. A. et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23, 3906\u20133911 (2005).","journal-title":"J Clin Oncol"},{"key":"BFsrep34036_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.1128294","volume":"313","author":"U Ozcan","year":"2006","unstructured":"Ozcan, U. et al. Chemical chaperones reduce er stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137\u20131140 (2006).","journal-title":"Science"},{"key":"BFsrep34036_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.yexmp.2011.10.012","volume":"92","author":"P Ayala","year":"2011","unstructured":"Ayala, P. et al. Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. Exp Mol Pathol 92, 97\u2013104 (2011).","journal-title":"Exp Mol Pathol"},{"key":"BFsrep34036_CR11","first-page":"579","volume":"22","author":"I Svechnikova","year":"2003","unstructured":"Svechnikova, I. et al. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22, 579\u2013588 (2003).","journal-title":"Int J Oncol"},{"key":"BFsrep34036_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.105.559724","volume":"113","author":"HJ Kee","year":"2006","unstructured":"Kee, H. J. et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin ii infusion and aortic banding. Circulation 113, 51\u201359 (2006).","journal-title":"Circulation"},{"key":"BFsrep34036_CR13","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1161\/CIRCULATIONAHA.106.625467","volume":"113","author":"Y Kong","year":"2006","unstructured":"Kong, Y. et al. Suppression of class i and ii histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579\u20132588 (2006).","journal-title":"Circulation"},{"key":"BFsrep34036_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini, A. et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102, 14\u201325 (2010).","journal-title":"J Natl Cancer Inst"},{"key":"BFsrep34036_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nm1552","volume":"13","author":"CM Trivedi","year":"2007","unstructured":"Trivedi, C. M. et al. Hdac2 regulates the cardiac hypertrophic response by modulating gsk3 beta activity. Nat Med 13, 324\u2013331 (2007).","journal-title":"Nat Med"},{"key":"BFsrep34036_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-642-21631-2_4","volume":"206","author":"TA McKinsey","year":"2011","unstructured":"McKinsey, T. A. The biology and therapeutic implications of hdacs in the heart. Handb Exp Pharmacol 206, 57\u201378 (2011).","journal-title":"Handb Exp Pharmacol"},{"key":"BFsrep34036_CR17","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","volume":"24","author":"S Chang","year":"2004","unstructured":"Chang, S. et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24, 8467\u20138476 (2004).","journal-title":"Mol Cell Biol"},{"key":"BFsrep34036_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0092-8674(02)00861-9","volume":"110","author":"CL Zhang","year":"2002","unstructured":"Zhang, C. L. et al. Class ii histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479\u2013488 (2002).","journal-title":"Cell"},{"key":"BFsrep34036_CR19","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1172\/JCI37694","volume":"119","author":"M Maillet","year":"2009","unstructured":"Maillet, M. et al. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest 119, 3079\u20133088 (2009).","journal-title":"J Clin Invest"},{"key":"BFsrep34036_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1172\/JCI19137","volume":"112","author":"H Kook","year":"2003","unstructured":"Kook, H. et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein hop. J Clin Invest 112, 863\u2013871 (2003).","journal-title":"J Clin Invest"},{"key":"BFsrep34036_CR21","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1101\/gad.1563807","volume":"21","author":"RL Montgomery","year":"2007","unstructured":"Montgomery, R. L. et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth and contractility. Genes Dev 21, 1790\u20131802 (2007).","journal-title":"Genes Dev"},{"key":"BFsrep34036_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1043-2760(01)00438-6","volume":"12","author":"OH Kramer","year":"2001","unstructured":"Kramer, O. H., Gottlicher, M. & Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12, 294\u2013300 (2001).","journal-title":"Trends Endocrinol Metab"},{"key":"BFsrep34036_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0959-437X(99)80026-4","volume":"9","author":"SY Archer","year":"1999","unstructured":"Archer, S. Y. & Hodin, R. A. Histone acetylation and cancer. Curr Opin Genet Dev 9, 171\u2013174 (1999).","journal-title":"Curr Opin Genet Dev"},{"key":"BFsrep34036_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml1001954","volume":"2","author":"DM Fass","year":"2010","unstructured":"Fass, D. M. et al. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett 2, 39\u201342 (2010).","journal-title":"ACS Med Chem Lett"},{"key":"BFsrep34036_CR25","doi-asserted-by":"publisher","first-page":"e73589","DOI":"10.1371\/journal.pone.0073589","volume":"8","author":"CE Winbanks","year":"2013","unstructured":"Winbanks, C. E. et al. Mir-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of hdac4. PLoS One 8, e73589 (2013).","journal-title":"PLoS One"},{"key":"BFsrep34036_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.7150\/jca.12135","volume":"6","author":"G Sun","year":"2015","unstructured":"Sun, G., Mackey, L. V., Coy, D. H., Yu, C. Y. & Sun, L. The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing notch signaling. J Cancer 6, 996\u20131004 (2015).","journal-title":"J Cancer"},{"key":"BFsrep34036_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","volume":"24","author":"L Sun","year":"2016","unstructured":"Sun, L. et al. Valproic acid induces net cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type ii. J Drug Target 24, 169\u2013177 (2016).","journal-title":"J Drug Target"},{"key":"BFsrep34036_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.yexmp.2015.01.003","volume":"98","author":"S Khan","year":"2015","unstructured":"Khan, S., Jena, G. & Tikoo, K. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. Exp Mol Pathol 98, 230\u2013239 (2015).","journal-title":"Exp Mol Pathol"},{"key":"BFsrep34036_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000350148","volume":"37","author":"HJ Kee","year":"2013","unstructured":"Kee, H. J. et al. Hdac inhibition suppresses cardiac hypertrophy and fibrosis in doca-salt hypertensive rats via regulation of hdac6\/hdac8 enzyme activity. Kidney Blood Press Res 37, 229\u2013239 (2013).","journal-title":"Kidney Blood Press Res"},{"key":"BFsrep34036_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.cardiores.2006.11.036","volume":"73","author":"TA McKinsey","year":"2007","unstructured":"McKinsey, T. A. Derepression of pathological cardiac genes by members of the cam kinase superfamily. Cardiovasc Res 73, 667\u2013677 (2007).","journal-title":"Cardiovasc Res"},{"key":"BFsrep34036_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142422","volume":"75","author":"A Shilatifard","year":"2006","unstructured":"Shilatifard, A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem 75, 243\u2013269 (2006).","journal-title":"Annu Rev Biochem"},{"key":"BFsrep34036_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"MA Glozak","year":"2005","unstructured":"Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15\u201323 (2005).","journal-title":"Gene"},{"key":"BFsrep34036_CR33","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1128\/MCB.23.10.3593-3606.2003","volume":"23","author":"T Yanazume","year":"2003","unstructured":"Yanazume, T. et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 23, 3593\u20133606 (2003).","journal-title":"Mol Cell Biol"},{"key":"BFsrep34036_CR34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.RES.0000218781.23144.3e","volume":"98","author":"W Xing","year":"2006","unstructured":"Xing, W. et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 98, 1089\u20131097 (2006).","journal-title":"Circ Res"},{"key":"BFsrep34036_CR35","doi-asserted-by":"publisher","first-page":"9936","DOI":"10.1128\/MCB.25.22.9936-9948.2005","volume":"25","author":"YS Dai","year":"2005","unstructured":"Dai, Y. S., Xu, J. & Molkentin, J. D. The dnaj-related factor mrj interacts with nuclear factor of activated t cells c3 and mediates transcriptional repression through class ii histone deacetylase recruitment. Mol Cell Biol 25, 9936\u20139948 (2005).","journal-title":"Mol Cell Biol"},{"key":"BFsrep34036_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cell.2006.02.048","volume":"125","author":"K Song","year":"2006","unstructured":"Song, K. et al. The transcriptional coactivator camta2 stimulates cardiac growth by opposing class ii histone deacetylases. Cell 125, 453\u2013466 (2006).","journal-title":"Cell"},{"key":"BFsrep34036_CR37","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1128\/MCB.25.9.3575-3582.2005","volume":"25","author":"K Ma","year":"2005","unstructured":"Ma, K., Chan, J. K., Zhu, G. & Wu, Z. Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity and myogenic differentiation. Mol Cell Biol 25, 3575\u20133582 (2005).","journal-title":"Mol Cell Biol"},{"key":"BFsrep34036_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1124\/jpet.107.135186","volume":"326","author":"T Roque","year":"2008","unstructured":"Roque, T. et al. Proinflammatory effect of sodium 4-phenylbutyrate in deltaf508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: Involvement of extracellular signal-regulated protein kinase 1\/2 and c-jun-nh2-terminal kinase signaling. J Pharmacol Exp Ther 326, 949\u2013956 (2008).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep34036_CR39","first-page":"1477","volume":"61","author":"R Pili","year":"2001","unstructured":"Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61, 1477\u20131485 (2001).","journal-title":"Cancer Res"},{"key":"BFsrep34036_CR40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/CIRCRESAHA.115.307604","volume":"118","author":"HY Fu","year":"2016","unstructured":"Fu, H. Y. et al. Chemical endoplasmic reticulum chaperone alleviates doxorubicin-induced cardiac dysfunction. Circ Res 118, 798\u2013809 (2016).","journal-title":"Circ Res"},{"key":"BFsrep34036_CR41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.yjmcc.2011.04.017","volume":"51","author":"JJ Leenders","year":"2011","unstructured":"Leenders, J. J., Pinto, Y. M. & Creemers, E. E. Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling. J Mol Cell Cardiol 51, 156\u2013167 (2011).","journal-title":"J Mol Cell Cardiol"},{"key":"BFsrep34036_CR42","doi-asserted-by":"crossref","unstructured":"Rose, B. A., Force, T. & Wang, Y. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev 90, 1507\u20131546.","DOI":"10.1152\/physrev.00054.2009"},{"key":"BFsrep34036_CR43","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1152\/physiolgenomics.00048.2011","volume":"43","author":"G Majumdar","year":"2011","unstructured":"Majumdar, G., Rooney, R. J., Johnson, I. M. & Raghow, R. Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy. Physiol Genomics 43, 1319\u20131333 (2011).","journal-title":"Physiol Genomics"},{"key":"BFsrep34036_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.yjmcc.2009.08.022","volume":"47","author":"HJ Kee","year":"2009","unstructured":"Kee, H. J. & Kook, H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 47, 770\u2013780 (2009).","journal-title":"J Mol Cell Cardiol"},{"key":"BFsrep34036_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm0102-35","volume":"8","author":"M Asakura","year":"2002","unstructured":"Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of adam12 processing of hb-egf: Metalloproteinase inhibitors as a new therapy. Nat Med 8, 35\u201340 (2002).","journal-title":"Nat Med"},{"key":"BFsrep34036_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1042\/CS20140586","volume":"128","author":"L Shen","year":"2015","unstructured":"Shen, L. et al. Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by promoting p53 activation and mitochondrial dysfunction in rodents. Clin Sci (Lond) 128, 665\u2013678 (2015).","journal-title":"Clin Sci (Lond)"},{"key":"BFsrep34036_CR47","doi-asserted-by":"publisher","first-page":"H1703","DOI":"10.1152\/ajpheart.00238.2001","volume":"282","author":"Y Liao","year":"2002","unstructured":"Liao, Y. et al. Echocardiographic assessment of lv hypertrophy and function in aortic-banded mice: Necropsy validation. Am J Physiol Heart Circ Physiol 282, H1703\u2013H1708 (2002).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep34036_CR48","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1161\/CIRCULATIONAHA.114.013789","volume":"131","author":"X Wei","year":"2015","unstructured":"Wei, X. et al. Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of s100a8\/a9. Circulation 131, 1506\u20131517, discussion 1517 (2015).","journal-title":"Circulation"},{"key":"BFsrep34036_CR49","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian, G. et al. Neuroprotective effects of phenylbutyrate in the n171-82q transgenic mouse model of huntington\u2019s disease. J Biol Chem. 280, 556\u2013563 (2005).","journal-title":"J Biol Chem."},{"key":"BFsrep34036_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cardiores.2006.01.021","volume":"70","author":"Y Liao","year":"2006","unstructured":"Liao, Y. et al. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovasc Res. 70, 107\u2013116 (2006).","journal-title":"Cardiovasc Res."},{"key":"BFsrep34036_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/01.CIR.0000137831.08683.E1","volume":"110","author":"Y Liao","year":"2004","unstructured":"Liao, Y. et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110, 692\u2013699 (2004).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep34036","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T22:13:50Z","timestamp":1672870430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep34036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]}},"alternative-id":["BFsrep34036"],"URL":"https:\/\/doi.org\/10.1038\/srep34036","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]},"assertion":[{"value":"12 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34036"}}